
© 2024 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
92,74 | 94,44 | 11:18 | |
93,92 | 94,90 | 25.04. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | Neurocrine Highlights INGREZZA's Long-Term Efficacy & Safety In Older Adults With Tardive Dyskinesia | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, demonstrating the long-term... ► Artikel lesen | |
Do | Neurocrine Biosciences publishes positive data from movement disorder study | ||
Mi | Stifel maintains Buy on Neurocrine stock, $166 target | ||
Di | Neurocrine Bio shares target cut to $168 by H.C. Wainwright | ||
15.04. | What 16 Analyst Ratings Have To Say About Neurocrine Biosciences |